Development of a new pharmacological treatment for chronic wounds, identified by implementation of the first assay platform for personalized medicine of chronic wounds. The proprietary assays combine diagnosis and therapy recommendations for individual chronic wound patients. A Ph1b/2a proof-of-concept study is planned for 2025.
Contact: